CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

New Condition-Level Review Aims to Close Evidence Gaps in Tuberculosis Care

Published on: March 24, 2021
Result type: News

More than 35 evidence reviews are mapped to the prevention, identification, treatment, and management of tuberculosis, and accessible on a digital platform

With the publication of its first condition-level review, CADTH is giving Canadian policy-makers, clinicians, and patients quick access to evidence on a range of health technologies used to diagnose, treat, and manage tuberculosis (TB) — one of the world’s most serious infectious diseases.

Condition-level reviews are intended to inform decision-making about the overall management of a condition. Rather than assessing the evidence for a single therapy or diagnostic test, CADTH has examined a range of TB-related topics that span screening, diagnostics, drug regimens, support programs, and more. The evidence has been synthesized, appraised, and mapped to 4 broad categories of care on a user-friendly digital platform. For each completed report, users can quickly see the population and intervention of interest, scan key messages, and click through to the full publication. An evidence map offers a visual representation that can help identify knowledge gaps.

CADTH launched this work on Wednesday, March 24 to mark World TB Day — a WHO public health campaign that raises awareness of the global TB epidemic. Although Canada has a low rate of TB overall, the disease remains a significant concern in communities that experience higher rates of poverty, crowded living conditions, and poor access to health care.

Related Information:

CADTH would like to acknowledge Research Methods and Recommendations at McMaster University, Michael G. DeGroote Cochrane Canada Centre, WHO Collaborating Centre for Infectious Diseases, and Evidence Prime, for their assistance in developing our digital evidence platform.